2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. Interleukin Related Antagonist

Interleukin Related Antagonist

Interleukin Related Isoform Comparison

Interleukin Related Antagonists (18):

Cat. No. Product Name Effect Purity
  • HY-108841
    Raleukin
    		Antagonist 99.40%
    Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects.
  • HY-P10587
    Icotrokinra
    		Antagonist 99.89%
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
  • HY-P10284
    S7
    		Antagonist 99.12%
    S7 is an IL-6 receptor antagonist and inhibits the binding between IL-6 and IL-6R. S7 can inhibit angiogenesis and tumor growth.
  • HY-P9917
    Tocilizumab
    		Antagonist 99.67%
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
  • HY-101913
    IL-17A antagonist 1
    		Antagonist 99.74%
    IL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a Kd of 0.66 μM and an IC50 of 1.14 μM.
  • HY-P99280
    Bimekizumab
    		Antagonist
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.
  • HY-P99256
    Tildrakizumab
    		Antagonist
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.
  • HY-P99412
    Lusvertikimab
    		Antagonist 99.41%
    Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research.
  • HY-P9949
    Reslizumab
    		Antagonist 99.40%
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
  • HY-18263C
    Elubrixin tosylate
    		Antagonist 99.78%
    Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
  • HY-P9927A
    Anti-Human IL-17A
    		Antagonist
    Anti-Human IL-17A is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.
  • HY-P3450
    Erepdekinra
    		Antagonist 98.60%
    Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist.
  • HY-101915
    IL-17A antagonist 3
    		Antagonist 98.55%
    IL-17A antagonist 3 is an IL-17A antagonist, compound 3.
  • HY-P99645
    Goflikicept
    		Antagonist 98.32%
    Goflikicept (RPH 104) is a hybrid protein that selectively binds and inactivates both circulating IL-1ß and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI).
  • HY-148693
    OSM-SMI-8
    		Antagonist
    OSM-SMI-8 (NSC642624) is a potent OSM (oncostatin M) antagonist. OSM-SMI-8 has the potential for the research of cancer.
  • HY-18263A
    Elubrixin
    		Antagonist
    Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
  • HY-18263
    Elubrixin hydrochloride
    		Antagonist
    Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
  • HY-121743
    Ro26-4550
    		Antagonist
    Ro26-4550 is a low micromolar antagonist of IL-2/IL-2Rα binding with an IC50 value of 3 μM. Ro26-4550 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.